|
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC). |
|
|
Honoraria - Genentech/Roche; Genomic Health |
Consulting or Advisory Role - Celgene; GE Healthcare; GlaxoSmithKline; Pfizer |
Speakers' Bureau - Genentech/Roche; Genomic Health |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Genomic Health; Qfix; Varian Medical Systems |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Mannkind |
|
|
Consulting or Advisory Role - MD Anderson Cancer Center |
Research Funding - Elekta (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - 21st Century Oncology |
Consulting or Advisory Role - ImpediMed |
|
|
Leadership - Intrinsic LifeSciences (I) |
Stock and Other Ownership Interests - Intrinsic LifeSciences (I); Merganser Biotech (I); Silarus Therapeutics (I); xenon pharma (I) |
Consulting or Advisory Role - Keryx (I); Merganser Biotech (I); Silarus Therapeutics (I) |
Speakers' Bureau - Keryx (I) |
Research Funding - Keryx (I) |
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I) |
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I); Keryx (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - eviti; Nanthealth |
Honoraria - Bayer; Bristol-Myers Squibb; Lilly/ImClone |
Consulting or Advisory Role - eviti |
Research Funding - Abbvie (Inst) |
|
|
No Relationships to Disclose |